Would you consider omitting platinum from neoadjuvant chemotherapy in women > 50 years of age with localized triple negative breast cancer?

I would not use the results cited above from the >50 subgroup (which was just 30% of their study population) of the study from the Tata Memorial Centre to justify omission of carboplatin from the neoadjuvant regimen for TNBC in otherwise healthy patients over 50 with TNBC. There is compelling data f...

SABCS; Abstract GS5-01 2022 (page 4695 of the PDF) as presented by Dr. Gupta included 720 patients randomly assigned to receive paclitaxel alone (n = 355) or in combination with carboplatin (n = 365); followed by AC orEC, then standard surgery and radiotherapy. Based on subgroup analyses, the benefi...